TrialPath
Recruiting

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

NCT07688213 · Sanofi
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease
About this study
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study.
Eligibility criteria
Inclusion Criteria: * Participant must be 55 to 85 years (inclusive) of age, at the time of signing the informed consent. * Diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (National Institute on Aging-Alzheimer's Association \[NIA-AA\] Stage 3) or mild AD dementia (NIA-AA Stage 4). * Have a global Clinical Dementia Rating (CDR) score 0.5 to 1.0 and a CDR-Memory Box score ≥ 0.5 at screening. * Have a study partner who must provide separate written informed consent at screening. Study partner should be \>18 years of age, have known participant for at least 1 year, and have a minimum of 8 hours per week contact with participant. * The participant has evidence of cerebral amyloid pathology confirmed by positive visual read on amyloid positron emission tomography (PET) at screening. Exclusion Criteria: * The participant has any history of significant neurological disease including but not limited to, frontotemporal dementia, Lewy body dementia, Huntington's disease, serious infection of the brain, Parkinson's disease, multiple concussions, multiple sclerosis, or epilepsy or recurrent seizures (except febrile childhood seizures). * The participant has evidence of more than 4 microhemorrhages (\<10 mm in diameter) or superficial siderosis. * The participant carries two copies of the apolipoprotein-E epsilon 4 (APOE4) allele (APOE4/4). * The participant is currently receiving or has previously received any anti-amyloid immunotherapy (including, but not limited to, aducanumab, lecanemab, or donanemab) or triggering receptor expressed on myeloid cells 2 (TREM-2) targeting therapy. * The participant is currently receiving anticoagulant therapies. * The participant has had malignancy in the 3 years prior to Screening, excluding basal cell carcinoma, squamous cell carcinoma of the skin, melanoma in situ, Stage 1 or 2 prostate cancer, fully resected renal cell cancers, or cervical carcinoma in situ that has been successfully treated. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study design
Enrollment target: 160 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-07-28
Estimated completion: 2029-07-31
Last updated: 2026-11-06
Interventions
Drug: SAR448851Drug: Placebo
Primary outcomes
  • • Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217 (From baseline to Week 48)
  • • Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRS (From Week 48 to Week 96)
Sponsor
Sanofi · industry
Contacts & investigators
ContactTrial Transparency email recommended (Toll free for US & Canada) · contact · Contact-US@sanofi.com · 800-633-1610
All locations (32)
Healthy Brain Clinic- Site Number : 8400011Recruiting
Long Beach, California, United States
Oakland Clinical- Site Number : 8400010Recruiting
Oakland, California, United States
Aqualane Clinical Research- Site Number : 8400001Recruiting
Naples, Florida, United States
K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008Recruiting
Orlando, Florida, United States
Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014Recruiting
Stuart, Florida, United States
Axiom Brain Health- Site Number : 8400019Recruiting
Tampa, Florida, United States
Charter Research - Lady Lake- Site Number : 8400004Recruiting
The Villages, Florida, United States
Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012Recruiting
Wellington, Florida, United States
Boston Center for Memory - Newton- Site Number : 8400007Recruiting
Newton, Massachusetts, United States
The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005Recruiting
Springfield, New Jersey, United States
Summit Research Network - Portland - Northwest Vaughn Street- Site Number : 8400002Recruiting
Portland, Oregon, United States
Flourish Research - Keystone Clinical Studies- Site Number : 8400003Recruiting
Plymouth Meeting, Pennsylvania, United States
Rhode Island Mood & Memory Research Institute- Site Number : 8400015Recruiting
East Providence, Rhode Island, United States
Kerwin Medical Center- Site Number : 8400006Recruiting
Dallas, Texas, United States
Investigational Site Number : 0360001Recruiting
Macquarie Park, New South Wales, Australia
Investigational Site Number : 0360003Recruiting
Ivanhoe, Victoria, Australia
Investigational Site Number : 0360004Recruiting
Melbourne, Victoria, Australia
Investigational Site Number : 1240001Recruiting
Ottawa, Ontario, Canada
Investigational Site Number : 1240005Recruiting
Toronto, Ontario, Canada
Investigational Site Number : 1240008Recruiting
Montreal, Quebec, Canada
Investigational Site Number : 1560001Recruiting
Beijing, China
Investigational Site Number : 2760003Recruiting
Berlin, Germany
Investigational Site Number : 2760002Recruiting
Cologne, Germany
Investigational Site Number : 7240008Recruiting
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240006Recruiting
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240004Recruiting
Barcelona, Catalunya [Cataluña], Spain
Investigational Site Number : 7240003Recruiting
Pozuelo de Alarcón, Madrid, Spain
Investigational Site Number : 7240001Recruiting
Valencia, Spain
Investigational Site Number : 7240005Recruiting
Zaragoza, Spain
Investigational Site Number : 8260002Recruiting
London, Hammersmith and Fulham, United Kingdom
Investigational Site Number : 8260001Recruiting
London, London, City of, United Kingdom
Investigational Site Number : 8260004Recruiting
Bath, Somerset, United Kingdom
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease · TrialPath